Drug Profile
Nicotinamide riboside/pterostilbene - Elysium Health
Alternative Names: BASIS; EH 301Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Elysium Health
- Developer Elysium Health; University of South Alabama
- Class Amides; Nicotinic acids; Phytotherapies; Small molecules; Stilbenes; Vitamins
- Mechanism of Action Nicotinamide adenine dinucleotide modulators; SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute kidney injury
- Clinical Phase Unknown Menopausal syndrome
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Amyotrophic-lateral-sclerosis in Norway
- 15 Feb 2023 Elysium Health and University of Exeter withdraws prior to enrolment a phase I trial (In healthy volunteers) in United Kingdom (PO) (NCT04050358)
- 07 Oct 2021 Clinical trials in Amyotrophic lateral sclerosis in Norway (unspecified route) (NCT04562831)